Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.
about
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadBurkitt lymphoma in adolescents and young adults: management challenges.Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.International Pediatric Non-Hodgkin Lymphoma Response Criteria.Revised International Pediatric Non-Hodgkin Lymphoma Staging System.Burkitt lymphoma: staging and response evaluation.Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study ReportRituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaRisk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.The role of hematopoietic SCT in adult Burkitt lymphoma.Determining response and recurrence in pediatric B-cell lymphomas of the bone.Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience.Non-Hodgkin Lymphoma in Children.Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.
P2860
Q26797513-6A4B9CF9-AF99-4E90-9724-9E0D0E9B30AAQ30238965-4B5E9B0D-2464-4186-9C4D-DCA8A297E012Q34344942-1B211E74-6E3C-470E-B158-35C236FA23CBQ35708769-BFE71BD9-60CD-43B8-8C63-3E0B8404ED0AQ35708778-0395EA70-A0F1-48E9-B94A-6301DD40CCE2Q35798945-1D3A5A61-DDFF-47A6-B4F3-6F6A221707AAQ35855211-AC117F76-9F29-4B3D-9BE6-41962E1AF34AQ35963027-9C37595C-14FB-4074-9BD2-6DEF39694AC4Q36339717-3180A1CF-7184-4F69-8893-47CD355568F2Q37977133-0C5CD40A-DD29-44AD-AEF3-43944D0C0222Q38031733-98F8D874-B315-4132-8D00-3CEFF8467093Q38092047-7F62212D-011C-42E6-904D-8D4FAECDB557Q38097544-7AC751A8-A0A5-4FEB-9251-AEEAF499D38EQ38118167-1C7ED995-74C0-456F-A470-1EB5CA0600BBQ38547121-3B4C038C-885E-4552-B706-E6DBFF80A45FQ38687541-3B613774-E810-46D1-84C6-10084C04F214Q38782141-F1F541C8-EEE2-458A-93F7-ED7E3CC7BD77
P2860
Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Minimal disease assessment in ...... ldren's oncology group report.
@ast
Minimal disease assessment in ...... ldren's oncology group report.
@en
type
label
Minimal disease assessment in ...... ldren's oncology group report.
@ast
Minimal disease assessment in ...... ldren's oncology group report.
@en
prefLabel
Minimal disease assessment in ...... ldren's oncology group report.
@ast
Minimal disease assessment in ...... ldren's oncology group report.
@en
P2093
P2860
P1476
Minimal disease assessment in ...... ldren's oncology group report.
@en
P2093
Bruce Shiramizu
Erin Morris
James Lynch
Lauren Harrison
Lynette Smith
Melissa Agsalda
Mitchell S Cairo
Sherrie Perkins
Stanton Goldman
P2860
P304
P356
10.1111/J.1365-2141.2011.08681.X
P407
P577
2011-04-18T00:00:00Z